TL;DR
Molecular subtype-guided precision medicine now enables individualized systemic therapy for EBC via novel agents and biomarker-driven strategies, optimizing clinical decisions and improving outcomes.
Current treatment strategies across breast cancer subtypes are summarized, emerging therapies are highlighted, and the expanding APP role is emphasized.
INTRODUCTION Breast cancer is the most common cancer that affects women globally, with several molecular subtypes defined by hormone and growth factor receptor expression. While advances in understanding the biology of these subtypes have led to targeted therapies, aggressive forms, particularly Triple-Negative Breast...
INTRODUCTION Triple-negative breast cancers (TNBCs) are a type of breast cancer (BC) characterized by the absence of ER, PR, and HER2 expression. They account for 10-15% of invasive BC cases and are known for being aggressive and highly metastatic. TNBC patients face limited effective treatment options due to the inher...
Key approaches targeting DNA repair deficiency, immune regulation, oncogenic signaling pathways, and antigen-directed therapies are highlighted, and their clinical development and application are discussed.
This framework integrates evidence level, disease stage, biomarker reliability and patient tolerance into treatment selection for TNBC precision therapy and distinguish them from maturing or exploratory strategies such as pathway-directed therapy, epigenetic modulation, anti-vascular combinations, regulated cell-death...
BACKGROUND Pathologic complete response (pCR) is a key endpoint of neoadjuvant therapy in early-stage breast cancer (EBC), associated with improved survival, particularly in triple-negative and human epidermal growth factor receptor 2 (HER2)-positive disease. More recently, antibody-drug conjugates (ADCs), established...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
